Skip to main content
Erschienen in: Clinical Pharmacokinetics 13/2003

01.11.2003 | Leading Article

Dietary Effects on Drug Metabolism and Transport

verfasst von: Dr Robert Z. Harris, Graham R. Jang, Shirley Tsunoda

Erschienen in: Clinical Pharmacokinetics | Ausgabe 13/2003

Einloggen, um Zugang zu erhalten

Abstract

Metabolic food-drug interactions occur when the consumption of a particular food modulates the activity of a drug-metabolising enzyme system, resulting in an alteration of the pharmacokinetics of drugs metabolised by that system. A number of these interactions have been reported. Foods that contain complex mixtures of phytochemicals, such as fruits, vegetables, herbs, spices and teas, have the greatest potential to induce or inhibit the activity of drug-metabolising enzymes, although dietary macroconstituents (i.e. total protein, fat and carbohydrate ratios, and total energy intake) can also have effects. Particularly large interactions may result from the consumption of herbal dietary supplements.
Cytochrome P450 (CYP) 3A4 appears to be especially sensitive to dietary effects, as demonstrated by reports of potentially clinically important interactions involving orally administered drugs that are substrates of this enzyme. For example, interactions of grapefruit juice with cyclosporin and felodipine, St John’s wort with cyclosporin and indinavir, and red wine with cyclosporin, have the potential to require dosage adjustment to maintain drug concentrations within their therapeutic windows. The susceptibility of CYP3A4 to modulation by food constituents may be related to its high level of expression in the intestine, as well as its broad substrate specificity. Reported ethnic differences in the activity of this enzyme may be partly due to dietary factors.
Food-drug interactions involving CYP1A2, CYP2E1, glucuronosyltransferases and glutathione S-transferases have also been documented, although most of these interactions are modest in magnitude and clinically relevant only for drugs that have a narrow therapeutic range. Recently, interactions involving drug transporters, including P-glycoprotein and the organic anion transporting polypeptide, have also been identified. Further research is needed to determine the scope, magnitude and clinical importance of food effects on drug metabolism and transport.
Literatur
1.
Zurück zum Zitat Singh BN. Effects of food on clinical pharmacokinetics. Clin Pharmacokinet 1999; 37(3): 213–55PubMedCrossRef Singh BN. Effects of food on clinical pharmacokinetics. Clin Pharmacokinet 1999; 37(3): 213–55PubMedCrossRef
2.
Zurück zum Zitat US Food and Drug Administration. Guidance for industry. Food-effect bioavailability and fed bioequivalence studies. Rockville, MD: Food and Drug Administration, 2002. US Food and Drug Administration. Guidance for industry. Food-effect bioavailability and fed bioequivalence studies. Rockville, MD: Food and Drug Administration, 2002.
3.
Zurück zum Zitat Walter-Sack I, Klotz U. Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet 1996; 31(1): 47–64PubMedCrossRef Walter-Sack I, Klotz U. Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet 1996; 31(1): 47–64PubMedCrossRef
4.
Zurück zum Zitat Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. 3rd ed. Media (PA): Williams & Wilkins, 1995 Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. 3rd ed. Media (PA): Williams & Wilkins, 1995
5.
Zurück zum Zitat Conney AH, Buening MK, Pantuck EJ, et al. Regulation of human drug metabolism by dietary factors. Ciba Found Symp 1980; 76: 147–67PubMed Conney AH, Buening MK, Pantuck EJ, et al. Regulation of human drug metabolism by dietary factors. Ciba Found Symp 1980; 76: 147–67PubMed
6.
Zurück zum Zitat Tsunoda SM, Velez RL, von Moltke LL, et al. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther 1999; 66(5): 461–71PubMedCrossRef Tsunoda SM, Velez RL, von Moltke LL, et al. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther 1999; 66(5): 461–71PubMedCrossRef
7.
Zurück zum Zitat Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 56(6 Pt 1): 601–7PubMedCrossRef Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 56(6 Pt 1): 601–7PubMedCrossRef
8.
Zurück zum Zitat Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998; 46(1): 49–53PubMedPubMedCentralCrossRef Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998; 46(1): 49–53PubMedPubMedCentralCrossRef
9.
Zurück zum Zitat Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences [published erratum appears in JAMA 1993; 269: 2088]. JAMA 1993; 269(12): 1513–8PubMedCrossRef Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences [published erratum appears in JAMA 1993; 269: 2088]. JAMA 1993; 269(12): 1513–8PubMedCrossRef
10.
Zurück zum Zitat Raschetti R, Morgutti M, Menniti-Ippolito F, et al. Suspected adverse drug events requiring emergency department visits or hospital admissions. Eur J Clin Pharmacol 1999; 54(12): 959–63PubMedCrossRef Raschetti R, Morgutti M, Menniti-Ippolito F, et al. Suspected adverse drug events requiring emergency department visits or hospital admissions. Eur J Clin Pharmacol 1999; 54(12): 959–63PubMedCrossRef
11.
Zurück zum Zitat Szoka PR, Edgren RA. Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database. Fertil Steril 1988; 49(5 Suppl. 2): 31S–8SPubMed Szoka PR, Edgren RA. Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database. Fertil Steril 1988; 49(5 Suppl. 2): 31S–8SPubMed
12.
Zurück zum Zitat Smith DA, Abel SM, Hyland R, et al. Human cytochrome P450s: selectivity and measurement in vivo. Xenobiotica 1998; 28(12): 1095–128PubMedCrossRef Smith DA, Abel SM, Hyland R, et al. Human cytochrome P450s: selectivity and measurement in vivo. Xenobiotica 1998; 28(12): 1095–128PubMedCrossRef
14.
Zurück zum Zitat Kullak-Ublick GA, Ismair MG, Stieger B, et al. Organic aniontransporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 2001; 120: 525–33PubMedCrossRef Kullak-Ublick GA, Ismair MG, Stieger B, et al. Organic aniontransporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 2001; 120: 525–33PubMedCrossRef
15.
Zurück zum Zitat HsiangB, Zhu Y, Wang Z, et al. A novel human hepatic organic anion transporting polypeptide (OATP2): identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 1999; 274: 37161–8CrossRef HsiangB, Zhu Y, Wang Z, et al. A novel human hepatic organic anion transporting polypeptide (OATP2): identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 1999; 274: 37161–8CrossRef
16.
Zurück zum Zitat Tanigawara Y. Role of P-glycoprotein in drug disposition. Ther Drug Monit 2000; 22(1): 137–40PubMedCrossRef Tanigawara Y. Role of P-glycoprotein in drug disposition. Ther Drug Monit 2000; 22(1): 137–40PubMedCrossRef
17.
Zurück zum Zitat Miners JO, Mackenzie PI. Drug glucuronidation in humans. Pharmacol Ther 1991; 51(3): 347–69PubMedCrossRef Miners JO, Mackenzie PI. Drug glucuronidation in humans. Pharmacol Ther 1991; 51(3): 347–69PubMedCrossRef
18.
Zurück zum Zitat Cvetkovic M, Leake B, Fromm MF, et al. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 1999; 27: 866–71PubMed Cvetkovic M, Leake B, Fromm MF, et al. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 1999; 27: 866–71PubMed
19.
Zurück zum Zitat Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38(1): 41–57PubMedCrossRef Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38(1): 41–57PubMedCrossRef
20.
Zurück zum Zitat Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999; 39: 1–17PubMedCrossRef Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999; 39: 1–17PubMedCrossRef
21.
Zurück zum Zitat Hall SD, Thummel KE, Watkins PB, et al. Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos 1999; 27(2): 161–6PubMed Hall SD, Thummel KE, Watkins PB, et al. Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos 1999; 27(2): 161–6PubMed
22.
Zurück zum Zitat Kolars JC, Lown KS, Schmiedlin-Ren P, et al. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994; 4(5): 247–59PubMedCrossRef Kolars JC, Lown KS, Schmiedlin-Ren P, et al. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994; 4(5): 247–59PubMedCrossRef
23.
Zurück zum Zitat Watkins PB. Drug metabolism by cytochromes P450 in the liver and small bowel. Gastroenterol Clin North Am 1992; 21(3): 511–26PubMed Watkins PB. Drug metabolism by cytochromes P450 in the liver and small bowel. Gastroenterol Clin North Am 1992; 21(3): 511–26PubMed
24.
Zurück zum Zitat Gorski JC, Jones DR, Haehner-Daniels BD, et al. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998; 64(2): 133–43PubMedCrossRef Gorski JC, Jones DR, Haehner-Daniels BD, et al. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998; 64(2): 133–43PubMedCrossRef
25.
Zurück zum Zitat Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 1513–8PubMedCrossRef Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 1513–8PubMedCrossRef
26.
Zurück zum Zitat Back DJ, Bates M, Bowden A, et al. The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy. Contraception 1980; 22(5): 495–503PubMedCrossRef Back DJ, Bates M, Bowden A, et al. The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy. Contraception 1980; 22(5): 495–503PubMedCrossRef
27.
Zurück zum Zitat Offermann G, Keller F, Molzahn M. Low cyclosporin A blood levels and acute graft rejection in a renal transplant recipient during rifampin treatment. Am J Nephrol 1985; 5: 385–7PubMedCrossRef Offermann G, Keller F, Molzahn M. Low cyclosporin A blood levels and acute graft rejection in a renal transplant recipient during rifampin treatment. Am J Nephrol 1985; 5: 385–7PubMedCrossRef
28.
Zurück zum Zitat Tang W, Stearns RA. Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions. Curr Drug Metab 2001; 2(2): 185–98PubMedCrossRef Tang W, Stearns RA. Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions. Curr Drug Metab 2001; 2(2): 185–98PubMedCrossRef
29.
Zurück zum Zitat Shou M, Lin Y, Lu P, et al. Enzyme kinetics of cytochrome P450-mediated reactions. Curr Drug Metab 2001; 2(1): 17–36PubMedCrossRef Shou M, Lin Y, Lu P, et al. Enzyme kinetics of cytochrome P450-mediated reactions. Curr Drug Metab 2001; 2(1): 17–36PubMedCrossRef
30.
Zurück zum Zitat Schrag ML, Wienkers LC. Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains. Arch Biochem Biophys 2001; 391(1): 49–55PubMedCrossRef Schrag ML, Wienkers LC. Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains. Arch Biochem Biophys 2001; 391(1): 49–55PubMedCrossRef
31.
Zurück zum Zitat Ameer B, Weintraub RA. Drag interactions with grapefruit juice. Clin Pharmacokinet 1997; 33(2): 103–21PubMedCrossRef Ameer B, Weintraub RA. Drag interactions with grapefruit juice. Clin Pharmacokinet 1997; 33(2): 103–21PubMedCrossRef
33.
Zurück zum Zitat Fuhr U. Drug interactions with grapefruit juice: extent, probable mechanism and clinical relevance. Drag Saf 1998; 18(4): 251–72CrossRef Fuhr U. Drug interactions with grapefruit juice: extent, probable mechanism and clinical relevance. Drag Saf 1998; 18(4): 251–72CrossRef
34.
Zurück zum Zitat Ku YM, Min DI, Flanigan M. Effect of grapefruit juice on the pharmacokinetics of microemulsion cyclosporine and its metabolite in healthy volunteers: does the formulation difference matter?. J Clin Pharmacol 1998; 38(10): 959–65PubMedCrossRef Ku YM, Min DI, Flanigan M. Effect of grapefruit juice on the pharmacokinetics of microemulsion cyclosporine and its metabolite in healthy volunteers: does the formulation difference matter?. J Clin Pharmacol 1998; 38(10): 959–65PubMedCrossRef
35.
Zurück zum Zitat Min DI, Ku YM, Perry PJ, et al. Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients. Transplantation 1996; 62(1): 123–5PubMedCrossRef Min DI, Ku YM, Perry PJ, et al. Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients. Transplantation 1996; 62(1): 123–5PubMedCrossRef
36.
Zurück zum Zitat Proppe DG, Hoch OD, McLean AJ, et al. Influence of chronic ingestion of grapefruit juice on steady-state blood concentrations of cyclosporine A in renal transplant patients with stable graft function. Br J Clin Pharmacol 1995; 39(3): 337–8PubMedPubMedCentralCrossRef Proppe DG, Hoch OD, McLean AJ, et al. Influence of chronic ingestion of grapefruit juice on steady-state blood concentrations of cyclosporine A in renal transplant patients with stable graft function. Br J Clin Pharmacol 1995; 39(3): 337–8PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Benton RE, Honig PK, Zamani K, et al. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther 1996; 59(4): 383–8PubMedCrossRef Benton RE, Honig PK, Zamani K, et al. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther 1996; 59(4): 383–8PubMedCrossRef
38.
Zurück zum Zitat Clifford CP, Adams DA, Murray S, et al. The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice. Eur J Clin Pharmacol 1997; 52(4): 311–5PubMedCrossRef Clifford CP, Adams DA, Murray S, et al. The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice. Eur J Clin Pharmacol 1997; 52(4): 311–5PubMedCrossRef
39.
Zurück zum Zitat Honig PK, Wortham DC, Lazarev A, et al. Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine. J Clin Pharmacol 1996; 36(4): 345–51PubMedCrossRef Honig PK, Wortham DC, Lazarev A, et al. Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine. J Clin Pharmacol 1996; 36(4): 345–51PubMedCrossRef
40.
Zurück zum Zitat Goho C. Oral midazolam-grapefrait juice drug interaction. Pediatr Dent 2001; 23(4): 365–6PubMed Goho C. Oral midazolam-grapefrait juice drug interaction. Pediatr Dent 2001; 23(4): 365–6PubMed
41.
Zurück zum Zitat Kupferschmidt HH, Ha HR, Ziegler WH, et al. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995; 58(1): 20–8PubMedCrossRef Kupferschmidt HH, Ha HR, Ziegler WH, et al. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995; 58(1): 20–8PubMedCrossRef
42.
Zurück zum Zitat Bailey DG, Arnold JM, Bend JR, et al. Grapefruit juicefelodipine interaction: reproducibility and characterization with the extended release drag formulation. Br J Clin Pharmacol 1995; 40(2): 135–40PubMedPubMedCentral Bailey DG, Arnold JM, Bend JR, et al. Grapefruit juicefelodipine interaction: reproducibility and characterization with the extended release drag formulation. Br J Clin Pharmacol 1995; 40(2): 135–40PubMedPubMedCentral
43.
Zurück zum Zitat Edgar B, Bailey D, Bergstrand R, et al. Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine: and its potential clinical relevance. Eur J Clin Pharmacol 1992; 42(3): 313–7PubMedCrossRef Edgar B, Bailey D, Bergstrand R, et al. Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine: and its potential clinical relevance. Eur J Clin Pharmacol 1992; 42(3): 313–7PubMedCrossRef
44.
Zurück zum Zitat Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997; 99(10): 2545–53PubMedPubMedCentralCrossRef Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997; 99(10): 2545–53PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Feldman EB. How grapefruit juice potentiates drag bioavailability. Nutr Rev 1997; 55(11 Pt 1): 398–400PubMed Feldman EB. How grapefruit juice potentiates drag bioavailability. Nutr Rev 1997; 55(11 Pt 1): 398–400PubMed
46.
47.
Zurück zum Zitat Lilja JJ, Kivisto KT, Backman JT, et al. Effect of grapefruit juice dose on grapefruit juice-triazolam interaction: repeated consumption prolongs triazolam half-life. Eur J Clin Pharmacol 2000 Aug; 56(5): 411–5PubMedCrossRef Lilja JJ, Kivisto KT, Backman JT, et al. Effect of grapefruit juice dose on grapefruit juice-triazolam interaction: repeated consumption prolongs triazolam half-life. Eur J Clin Pharmacol 2000 Aug; 56(5): 411–5PubMedCrossRef
48.
Zurück zum Zitat Malhotra S, Bailey DG, Paine MF, et al. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther 2001; 69(1): 14–23PubMedCrossRef Malhotra S, Bailey DG, Paine MF, et al. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther 2001; 69(1): 14–23PubMedCrossRef
49.
Zurück zum Zitat Backman JT, Maenpaa J, Belle DJ, et al. Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation. Clin Pharmacol Ther 2000; 67(4): 382–90PubMedCrossRef Backman JT, Maenpaa J, Belle DJ, et al. Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation. Clin Pharmacol Ther 2000; 67(4): 382–90PubMedCrossRef
50.
Zurück zum Zitat Edwards DJ, Fitzsimmons ME, Schuetz EG, et al. 6′,7′-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharmacol Ther 1999; 65(3): 237–44PubMedCrossRef Edwards DJ, Fitzsimmons ME, Schuetz EG, et al. 6′,7′-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharmacol Ther 1999; 65(3): 237–44PubMedCrossRef
51.
Zurück zum Zitat Wollin SD, Jones PJ. Alcohol, red wine and cardiovascular disease. J Nutr 2001; 131(5): 1401–4PubMed Wollin SD, Jones PJ. Alcohol, red wine and cardiovascular disease. J Nutr 2001; 131(5): 1401–4PubMed
52.
Zurück zum Zitat Mukamal KJ, Maclure M, Muller JE, et al. Prior alcohol consumption and mortality following acute myocardial infarction. JAMA 2001; 285(15): 1965–70PubMedCrossRef Mukamal KJ, Maclure M, Muller JE, et al. Prior alcohol consumption and mortality following acute myocardial infarction. JAMA 2001; 285(15): 1965–70PubMedCrossRef
54.
Zurück zum Zitat Renaud S, Gueguen R. The French paradox and wine drinking. Novartis Found Symp 1998; 216: 208–17PubMed Renaud S, Gueguen R. The French paradox and wine drinking. Novartis Found Symp 1998; 216: 208–17PubMed
55.
Zurück zum Zitat Chan WK, Nguyen LT, Miller VP, et al. Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine. Life Sci 1998; 62(10): L135–42CrossRef Chan WK, Nguyen LT, Miller VP, et al. Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine. Life Sci 1998; 62(10): L135–42CrossRef
56.
Zurück zum Zitat Chang TK, Yeung RK. Effect of trans-resveratrol on 7-benzyloxy-4-trifluoromethylcoumarin O-dealkylation catalyzed by human recombinant CYP3A4 and CYP3A5. Can J Physiol Pharmacol 2001; 79(3): 220–6PubMedCrossRef Chang TK, Yeung RK. Effect of trans-resveratrol on 7-benzyloxy-4-trifluoromethylcoumarin O-dealkylation catalyzed by human recombinant CYP3A4 and CYP3A5. Can J Physiol Pharmacol 2001; 79(3): 220–6PubMedCrossRef
57.
Zurück zum Zitat Chan WK, Delucchi AB. Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci 2000; 67(25): 3103–12PubMedCrossRef Chan WK, Delucchi AB. Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci 2000; 67(25): 3103–12PubMedCrossRef
58.
Zurück zum Zitat Piver B, Berthou F, Dreano Y, et al. Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol Lett 2001; 125(1–3): 83–91PubMedCrossRef Piver B, Berthou F, Dreano Y, et al. Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol Lett 2001; 125(1–3): 83–91PubMedCrossRef
59.
Zurück zum Zitat Tsunoda SM, Harris RZ, Christians U, et al. Red wine decreases cyclosporine bioavailability. Clin Pharmacol Ther 2001; 70(5): 462–7PubMedCrossRef Tsunoda SM, Harris RZ, Christians U, et al. Red wine decreases cyclosporine bioavailability. Clin Pharmacol Ther 2001; 70(5): 462–7PubMedCrossRef
60.
Zurück zum Zitat Tsunoda SM, Harris RZ, Freeman RB, et al. Acute and chronic wine effects on cyclosporine (CYA) disposition. Br J Clin Pharmacol 2000, 42 Tsunoda SM, Harris RZ, Freeman RB, et al. Acute and chronic wine effects on cyclosporine (CYA) disposition. Br J Clin Pharmacol 2000, 42
61.
Zurück zum Zitat Offman EM, Freeman DJ, Dresser GK, et al. Red winecisapride interaction: comparison with grapefruit juice. Clin Pharmacol Ther 2001; 70(1): 17–23PubMedCrossRef Offman EM, Freeman DJ, Dresser GK, et al. Red winecisapride interaction: comparison with grapefruit juice. Clin Pharmacol Ther 2001; 70(1): 17–23PubMedCrossRef
62.
Zurück zum Zitat Nelson L, Perrone J. Herbal and alternative medicine. Emerg Med Clin North Am 2000; 18(4): 709–22PubMedCrossRef Nelson L, Perrone J. Herbal and alternative medicine. Emerg Med Clin North Am 2000; 18(4): 709–22PubMedCrossRef
63.
Zurück zum Zitat Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drags: a systematic review. Drags 2001; 61(15): 2163–75CrossRef Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drags: a systematic review. Drags 2001; 61(15): 2163–75CrossRef
64.
Zurück zum Zitat Barone GW, Gurley BJ, Ketel BL, et al. Drug interaction between St John’s wort and cyclosporine. Ann Pharmacother 2000; 34(9): 1013–6PubMedCrossRef Barone GW, Gurley BJ, Ketel BL, et al. Drug interaction between St John’s wort and cyclosporine. Ann Pharmacother 2000; 34(9): 1013–6PubMedCrossRef
65.
Zurück zum Zitat Ruschitzka F, Meier PJ, Turina M, et al. Acute heart transplant rejection due to Saint John’s wort. Lancet 2000; 355(9203): 548–9PubMedCrossRef Ruschitzka F, Meier PJ, Turina M, et al. Acute heart transplant rejection due to Saint John’s wort. Lancet 2000; 355(9203): 548–9PubMedCrossRef
66.
Zurück zum Zitat Karliova M, Treichel U, Malago M, et al. Interaction of Hypericum perforatum (St John’s wort) with cyclosporin A metabolism in a patient after liver transplantation. J Hepatol 2000; 33(5): 853–5PubMedCrossRef Karliova M, Treichel U, Malago M, et al. Interaction of Hypericum perforatum (St John’s wort) with cyclosporin A metabolism in a patient after liver transplantation. J Hepatol 2000; 33(5): 853–5PubMedCrossRef
67.
Zurück zum Zitat Breidenbach T, Kliem V, Burg M, et al. Profound drop of cyclosporin A whole blood trough levels caused by St John’s wort (Hypericum perforatum). Transplantation 2000; 69(10): 2229–30PubMedCrossRef Breidenbach T, Kliem V, Burg M, et al. Profound drop of cyclosporin A whole blood trough levels caused by St John’s wort (Hypericum perforatum). Transplantation 2000; 69(10): 2229–30PubMedCrossRef
68.
Zurück zum Zitat Piscitelli SC, Burstein AH, ChaittD, et al. Indinavir concentrations and St John’s wort [published erratum appears in Lancet 2001; 357: 1210]. Lancet 2000; 355(9203): 547–8PubMedCrossRef Piscitelli SC, Burstein AH, ChaittD, et al. Indinavir concentrations and St John’s wort [published erratum appears in Lancet 2001; 357: 1210]. Lancet 2000; 355(9203): 547–8PubMedCrossRef
69.
Zurück zum Zitat Gorski JC, Hamman MA, Wang Z, et al. The effect of St John’s wort on the efficacy of oral contraception [abstract]. Clin Pharmacol Ther 2002; 71(2): P25 Gorski JC, Hamman MA, Wang Z, et al. The effect of St John’s wort on the efficacy of oral contraception [abstract]. Clin Pharmacol Ther 2002; 71(2): P25
70.
Zurück zum Zitat Markowitz JS, DeVane CL, Boulton DW, et al. Effect of St John’s wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci 2000; 66(9): L133–9CrossRef Markowitz JS, DeVane CL, Boulton DW, et al. Effect of St John’s wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci 2000; 66(9): L133–9CrossRef
71.
Zurück zum Zitat Wang Z, Gorski JC, Hamman MA, et al. The effects of St John’s wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001; 70(4): 317–26PubMed Wang Z, Gorski JC, Hamman MA, et al. The effects of St John’s wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001; 70(4): 317–26PubMed
72.
Zurück zum Zitat Moore LB, Goodwin B, Jones SA, et al. St John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A 2000; 97(13): 7500–2PubMedPubMedCentralCrossRef Moore LB, Goodwin B, Jones SA, et al. St John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A 2000; 97(13): 7500–2PubMedPubMedCentralCrossRef
73.
Zurück zum Zitat Foster BC, Foster MS, Vandenhoek S, et al. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci 2001; 4(2): 176–84PubMed Foster BC, Foster MS, Vandenhoek S, et al. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci 2001; 4(2): 176–84PubMed
74.
Zurück zum Zitat Piscitelli SC, Burstein AH, Weiden N, et al. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002; 34(2): 234–8PubMedCrossRef Piscitelli SC, Burstein AH, Weiden N, et al. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002; 34(2): 234–8PubMedCrossRef
75.
Zurück zum Zitat Ahsan CH, Renwick AG, Waller DG, et al. The influence of dose and ethnic origins on the pharmacokinetics of nifedipine. Clin Pharmacol Ther 1993; 54(3): 329–38PubMedCrossRef Ahsan CH, Renwick AG, Waller DG, et al. The influence of dose and ethnic origins on the pharmacokinetics of nifedipine. Clin Pharmacol Ther 1993; 54(3): 329–38PubMedCrossRef
76.
77.
Zurück zum Zitat Yu KS, Cho JY, Shon JH, et al. Ethnic differences and relationships in the oral pharmacokinetics of nifedipine and erythro-mycin. Clin Pharmacol Ther 2001; 70(3): 228–36PubMedCrossRef Yu KS, Cho JY, Shon JH, et al. Ethnic differences and relationships in the oral pharmacokinetics of nifedipine and erythro-mycin. Clin Pharmacol Ther 2001; 70(3): 228–36PubMedCrossRef
78.
Zurück zum Zitat Kinirons MT, Lang CC, He HB, et al. Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity. Br J Clin Pharmacol 1996; 41(1): 69–72PubMedCrossRef Kinirons MT, Lang CC, He HB, et al. Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity. Br J Clin Pharmacol 1996; 41(1): 69–72PubMedCrossRef
79.
Zurück zum Zitat Ahsan CH, Renwick AG, Macklin B, et al. Ethnic differences in the pharmacokinetics of oral nifedipine. Br J Clin Pharmacol 1991; 31(4): 399–403PubMedPubMedCentralCrossRef Ahsan CH, Renwick AG, Macklin B, et al. Ethnic differences in the pharmacokinetics of oral nifedipine. Br J Clin Pharmacol 1991; 31(4): 399–403PubMedPubMedCentralCrossRef
80.
Zurück zum Zitat Stein CM, Sadeque AJ, Murray JJ, et al. Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects. Clin Pharmacol Ther 2001; 69(5): 317–23PubMedCrossRef Stein CM, Sadeque AJ, Murray JJ, et al. Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects. Clin Pharmacol Ther 2001; 69(5): 317–23PubMedCrossRef
81.
Zurück zum Zitat Wandel C, Witte JS, Hall JM, et al. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B 5′-promoter region polymorphism. Clin Pharmacol Ther 2000; 68(1): 82–91PubMedCrossRef Wandel C, Witte JS, Hall JM, et al. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B 5′-promoter region polymorphism. Clin Pharmacol Ther 2000; 68(1): 82–91PubMedCrossRef
82.
Zurück zum Zitat Castaneda-Hernandez G, Palma-Aguirre JA, Montoya-Cabrera MA, et al. Interethnic variability in nifedipine disposition: reduced systemic plasma clearance in Mexican subjects. Br J Clin Pharmacol 1996; 41(5): 433–4PubMed Castaneda-Hernandez G, Palma-Aguirre JA, Montoya-Cabrera MA, et al. Interethnic variability in nifedipine disposition: reduced systemic plasma clearance in Mexican subjects. Br J Clin Pharmacol 1996; 41(5): 433–4PubMed
83.
Zurück zum Zitat Palma-Aguirre JA, Gonzalez-Llaven J, Flores-Murrieta FJ, et al. Bioavailability of oral cyclosporine in healthy Mexican volunteers: evidence for interethnic variability. J Clin Pharmacol 1997; 37(7): 630–4PubMedCrossRef Palma-Aguirre JA, Gonzalez-Llaven J, Flores-Murrieta FJ, et al. Bioavailability of oral cyclosporine in healthy Mexican volunteers: evidence for interethnic variability. J Clin Pharmacol 1997; 37(7): 630–4PubMedCrossRef
84.
Zurück zum Zitat Miners JO, McKinnon RA. CYP1A. In: Levy RH, Thummel KE, Trager WF, et al., editors. Metabolic drug interactions. Philadelphia: Lippincott Williams & Wilkins, 2000: 61–73 Miners JO, McKinnon RA. CYP1A. In: Levy RH, Thummel KE, Trager WF, et al., editors. Metabolic drug interactions. Philadelphia: Lippincott Williams & Wilkins, 2000: 61–73
85.
Zurück zum Zitat Jang GR, Maurel JP. Rifampin, dexamethasone, and omeprazole. In: Levy RH, Thummel KE, Trager WF, et al., editors. Metabolic drug interactions. Philadelphia (PA): Lippincott Williams & Wilkins, 2000: 691–706 Jang GR, Maurel JP. Rifampin, dexamethasone, and omeprazole. In: Levy RH, Thummel KE, Trager WF, et al., editors. Metabolic drug interactions. Philadelphia (PA): Lippincott Williams & Wilkins, 2000: 691–706
86.
Zurück zum Zitat Ayalogu EO, Snelling J, Lewis DF, et al. Induction of hepatic CYP1A2 by the oral administration of caffeine to rats: lack of association with the Ah locus. Biochim Biophys Acta 1995; 1272(2): 89–94PubMedCrossRef Ayalogu EO, Snelling J, Lewis DF, et al. Induction of hepatic CYP1A2 by the oral administration of caffeine to rats: lack of association with the Ah locus. Biochim Biophys Acta 1995; 1272(2): 89–94PubMedCrossRef
87.
Zurück zum Zitat Chen L, Bondoc FY, Lee MJ, et al. Caffeine induces cytochrome P4501A2: induction of CYP1A2 by tea in rats. Drug Metab Dispos 1996; 24(5): 529–33PubMed Chen L, Bondoc FY, Lee MJ, et al. Caffeine induces cytochrome P4501A2: induction of CYP1A2 by tea in rats. Drug Metab Dispos 1996; 24(5): 529–33PubMed
88.
Zurück zum Zitat Goasduff T, Dreano Y, Guillois B, et al. Induction of liver and kidney CYP1A1/1A2 by caffeine in rat. Biochem Pharmacol 1996; 52(12): 1915–9PubMedCrossRef Goasduff T, Dreano Y, Guillois B, et al. Induction of liver and kidney CYP1A1/1A2 by caffeine in rat. Biochem Pharmacol 1996; 52(12): 1915–9PubMedCrossRef
89.
Zurück zum Zitat Caraco Y, Zylber-Katz E, Granit L, et al. Does restriction of caffeine intake affect mixed function oxidase activity and caffeine metabolism?. Biopharm Drug Dispos 1990; 11(7): 639–43PubMedCrossRef Caraco Y, Zylber-Katz E, Granit L, et al. Does restriction of caffeine intake affect mixed function oxidase activity and caffeine metabolism?. Biopharm Drug Dispos 1990; 11(7): 639–43PubMedCrossRef
90.
Zurück zum Zitat Fuhr U, Kummert AL. The fate of naringin in humans: a key to grapefruit juice-drug interactions?. Clin Pharmacol Ther 1995; 58(4): 365–73PubMedCrossRef Fuhr U, Kummert AL. The fate of naringin in humans: a key to grapefruit juice-drug interactions?. Clin Pharmacol Ther 1995; 58(4): 365–73PubMedCrossRef
91.
Zurück zum Zitat Fuhr U, Klittich K, Staib AH. Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. Br J Clin Pharmacol 1993; 35(4): 431–6PubMedPubMedCentralCrossRef Fuhr U, Klittich K, Staib AH. Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. Br J Clin Pharmacol 1993; 35(4): 431–6PubMedPubMedCentralCrossRef
92.
Zurück zum Zitat Tassaneeyakul W, Guo LQ, Fukuda K, et al. Inhibition selectivity of grapefruit juice components on human cytochromes P450. Arch Biochem Biophys 2000; 378(2): 356–63PubMedCrossRef Tassaneeyakul W, Guo LQ, Fukuda K, et al. Inhibition selectivity of grapefruit juice components on human cytochromes P450. Arch Biochem Biophys 2000; 378(2): 356–63PubMedCrossRef
93.
Zurück zum Zitat Fuhr U, Maier A, Keller A, et al. Lacking effect of grapefruit juice on theophylline pharmacokinetics. Int J Clin Pharmacol Ther 1995; 33(6): 311–4PubMed Fuhr U, Maier A, Keller A, et al. Lacking effect of grapefruit juice on theophylline pharmacokinetics. Int J Clin Pharmacol Ther 1995; 33(6): 311–4PubMed
94.
Zurück zum Zitat Maish WA, Hampton EM, Whitsett TL, et al. Influence of grapefruit juice on caffeine pharmacokinetics and pharmacodynamics. Pharmacotherapy 1996; 16(6): 1046–52PubMed Maish WA, Hampton EM, Whitsett TL, et al. Influence of grapefruit juice on caffeine pharmacokinetics and pharmacodynamics. Pharmacotherapy 1996; 16(6): 1046–52PubMed
95.
Zurück zum Zitat Lane HY, Jann MW, Chang YC, et al. Repeated ingestion of grapefruit juice does not alter clozapine’s steady-state plasma levels, effectiveness, and tolerability. J Clin Psychiatry 2001; 62(10): 812–7PubMedCrossRef Lane HY, Jann MW, Chang YC, et al. Repeated ingestion of grapefruit juice does not alter clozapine’s steady-state plasma levels, effectiveness, and tolerability. J Clin Psychiatry 2001; 62(10): 812–7PubMedCrossRef
96.
Zurück zum Zitat Xiao DS, Zhi PZ, Zhong XW, et al. Possible enhancement of the first-pass metabolism of phenacetin by ingestion of grape juice in Chinese subjects. Br J Clin Pharmacol 1999; 48(4): 638–40CrossRef Xiao DS, Zhi PZ, Zhong XW, et al. Possible enhancement of the first-pass metabolism of phenacetin by ingestion of grape juice in Chinese subjects. Br J Clin Pharmacol 1999; 48(4): 638–40CrossRef
97.
Zurück zum Zitat Buening MK, Chang RL, Huang MT, et al. Activation and inhibition of benzo(a)pyrene and aflatoxin B1 metabolism in human liver microsomes by naturally occurring flavonoids. Cancer Res 1981; 41(1): 67–72PubMed Buening MK, Chang RL, Huang MT, et al. Activation and inhibition of benzo(a)pyrene and aflatoxin B1 metabolism in human liver microsomes by naturally occurring flavonoids. Cancer Res 1981; 41(1): 67–72PubMed
98.
Zurück zum Zitat Ekins S, Ring BJ, Binkley SN, et al. Autoactivation and activation of the cytochrome P450s. Int J Clin Pharmacol Ther 1998; 36(12): 642–51PubMed Ekins S, Ring BJ, Binkley SN, et al. Autoactivation and activation of the cytochrome P450s. Int J Clin Pharmacol Ther 1998; 36(12): 642–51PubMed
99.
Zurück zum Zitat Raaflaub J, Dubach UC. On the pharmacokinetics of phenacetin in man. Eur J Clin Pharmacol 1975; 8(3–4): 261–5PubMedCrossRef Raaflaub J, Dubach UC. On the pharmacokinetics of phenacetin in man. Eur J Clin Pharmacol 1975; 8(3–4): 261–5PubMedCrossRef
100.
Zurück zum Zitat Loub WD, Wattenberg LW, Davis DW. Aryl hydrocarbon hydroxylase induction in rat tissues by naturally occurring indoles of cruciferous plants. J Natl Cancer Inst 1975; 54(4): 985–8PubMed Loub WD, Wattenberg LW, Davis DW. Aryl hydrocarbon hydroxylase induction in rat tissues by naturally occurring indoles of cruciferous plants. J Natl Cancer Inst 1975; 54(4): 985–8PubMed
101.
Zurück zum Zitat Pantuck EJ, Hsiao KC, Loub WD, et al. Stimulatory effect of vegetables on intestinal drug metabolism in the rat. J Pharmacol Exp Ther 1976; 198(2): 278–83PubMed Pantuck EJ, Hsiao KC, Loub WD, et al. Stimulatory effect of vegetables on intestinal drug metabolism in the rat. J Pharmacol Exp Ther 1976; 198(2): 278–83PubMed
102.
Zurück zum Zitat Pantuck EJ, Pantuck CB, Garland WA, et al. Stimulatory effect of brussels sprouts and cabbage on human drug metabolism. Clin Pharmacol Ther 1979; 25(1): 88–95PubMedCrossRef Pantuck EJ, Pantuck CB, Garland WA, et al. Stimulatory effect of brussels sprouts and cabbage on human drug metabolism. Clin Pharmacol Ther 1979; 25(1): 88–95PubMedCrossRef
103.
Zurück zum Zitat Vistisen K, Poulsen HE, Loft S. Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine. Carcinogenesis 1992; 13(9): 1561–8PubMedCrossRef Vistisen K, Poulsen HE, Loft S. Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine. Carcinogenesis 1992; 13(9): 1561–8PubMedCrossRef
104.
Zurück zum Zitat Kall MA, Vang O, Clausen J. Effects of dietary broccoli on human in vivo drug metabolizing enzymes: evaluation of caffeine, oestrone and chlorzoxazone metabolism. Carcinogenesis 1996; 17(4): 793–9PubMedCrossRef Kall MA, Vang O, Clausen J. Effects of dietary broccoli on human in vivo drug metabolizing enzymes: evaluation of caffeine, oestrone and chlorzoxazone metabolism. Carcinogenesis 1996; 17(4): 793–9PubMedCrossRef
105.
Zurück zum Zitat Bonnesen C, Stephensen PU, Andersen O, et al. Modulation of cytochrome P-450 and glutathione S-transferase isoform expression in vivo by intact and degraded indolyl glucosinolates. Nutr Cancer 1999; 33(2): 178–87PubMedCrossRef Bonnesen C, Stephensen PU, Andersen O, et al. Modulation of cytochrome P-450 and glutathione S-transferase isoform expression in vivo by intact and degraded indolyl glucosinolates. Nutr Cancer 1999; 33(2): 178–87PubMedCrossRef
106.
Zurück zum Zitat Lampe JW, King IB, Li S, et al. Brassica vegetables increase and apiaceous vegetables decrease cytochrome P450 1A2 activity in humans: changes in caffeine metabolite ratios in response to controlled vegetable diets. Carcinogenesis 2000; 21(6): 1157–62PubMedCrossRef Lampe JW, King IB, Li S, et al. Brassica vegetables increase and apiaceous vegetables decrease cytochrome P450 1A2 activity in humans: changes in caffeine metabolite ratios in response to controlled vegetable diets. Carcinogenesis 2000; 21(6): 1157–62PubMedCrossRef
107.
Zurück zum Zitat Knize MG, Salmon CP, Pais P, et al. Food heating and the formation of heterocyclic aromatic amine and polycyclic aromatic hydrocarbon mutagens/carcinogens. Adv Exp Med Biol 1999; 459: 179–93PubMedCrossRef Knize MG, Salmon CP, Pais P, et al. Food heating and the formation of heterocyclic aromatic amine and polycyclic aromatic hydrocarbon mutagens/carcinogens. Adv Exp Med Biol 1999; 459: 179–93PubMedCrossRef
108.
109.
Zurück zum Zitat Conney AH, Pantuck EJ, Hsiao KC, et al. Enhanced phenacetin metabolism in human subjects fed charcoal-broiled beef. Clin Pharmacol Ther 1976; 20(6): 633–42PubMedCrossRef Conney AH, Pantuck EJ, Hsiao KC, et al. Enhanced phenacetin metabolism in human subjects fed charcoal-broiled beef. Clin Pharmacol Ther 1976; 20(6): 633–42PubMedCrossRef
110.
Zurück zum Zitat Sinha R, Rothman N, Brown ED, et al. Pan-fried meat containing high levels of heterocyclic aromatic amines but low levels of polycyclic aromatic hydrocarbons induces cytochrome P4501A2 activity in humans. Cancer Res 1994; 54(23): 6154–9PubMed Sinha R, Rothman N, Brown ED, et al. Pan-fried meat containing high levels of heterocyclic aromatic amines but low levels of polycyclic aromatic hydrocarbons induces cytochrome P4501A2 activity in humans. Cancer Res 1994; 54(23): 6154–9PubMed
111.
Zurück zum Zitat Fontana RJ, Lown KS, Paine MF, et al. Effects of a chargrilled meat diet on expression of CYP3A, CYP1 A, and P-glycoprotein levels in healthy volunteers. Gastroenterology 1999; 117(1): 89–98PubMedCrossRef Fontana RJ, Lown KS, Paine MF, et al. Effects of a chargrilled meat diet on expression of CYP3A, CYP1 A, and P-glycoprotein levels in healthy volunteers. Gastroenterology 1999; 117(1): 89–98PubMedCrossRef
112.
Zurück zum Zitat Turesky RJ, Lang NP, Butler MA, et al. Metabolic activation of carcinogenic heterocyclic aromatic amines by human liver and colon. Carcinogenesis 1991; 12(10): 1839–45PubMedCrossRef Turesky RJ, Lang NP, Butler MA, et al. Metabolic activation of carcinogenic heterocyclic aromatic amines by human liver and colon. Carcinogenesis 1991; 12(10): 1839–45PubMedCrossRef
113.
Zurück zum Zitat Hein DW, Doll MA, Rustan TD, et al. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 1993; 14(8): 1633–8PubMedCrossRef Hein DW, Doll MA, Rustan TD, et al. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 1993; 14(8): 1633–8PubMedCrossRef
114.
Zurück zum Zitat Boobis AR, Lynch AM, Murray S, et al. CYP1A2-catalyzed conversion of dietary heterocyclic amines to their proximate carcinogens is their major route of metabolism in humans. Cancer Res 1994; 54(1): 89–94PubMed Boobis AR, Lynch AM, Murray S, et al. CYP1A2-catalyzed conversion of dietary heterocyclic amines to their proximate carcinogens is their major route of metabolism in humans. Cancer Res 1994; 54(1): 89–94PubMed
115.
Zurück zum Zitat Steinkellner H, Rabot S, Freywald C, et al. Effects of cruciferous vegetables and their constituents on drug metabolizing enzymes involved in the bioactivation of DNA-reactive dietary carcinogens. Mutat Res 2001; 480(SI): 285–97PubMedCrossRef Steinkellner H, Rabot S, Freywald C, et al. Effects of cruciferous vegetables and their constituents on drug metabolizing enzymes involved in the bioactivation of DNA-reactive dietary carcinogens. Mutat Res 2001; 480(SI): 285–97PubMedCrossRef
116.
Zurück zum Zitat Le Marchand L, Hankin JH, Wilkens LR, et al. Combined effects of well-done red meat, smoking, and rapid N-Acetyl-transferase 2 and CYP1A2 phenotypes in increasing colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10(12): 1259–66PubMed Le Marchand L, Hankin JH, Wilkens LR, et al. Combined effects of well-done red meat, smoking, and rapid N-Acetyl-transferase 2 and CYP1A2 phenotypes in increasing colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10(12): 1259–66PubMed
117.
Zurück zum Zitat Raucy J, Carpenter SP. CYP2E1. In: Levy RH, Thummel KE, Trager WF, et al., editors. Metabolic drug interactions. Philadelphia (PA): Lippincott Williams & Wilkins, 2000: 95–114 Raucy J, Carpenter SP. CYP2E1. In: Levy RH, Thummel KE, Trager WF, et al., editors. Metabolic drug interactions. Philadelphia (PA): Lippincott Williams & Wilkins, 2000: 95–114
118.
Zurück zum Zitat Peter R, Bocker R, Beaune PH, et al. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxicol 1990; 3: 566–73PubMedCrossRef Peter R, Bocker R, Beaune PH, et al. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxicol 1990; 3: 566–73PubMedCrossRef
119.
Zurück zum Zitat Raucy JL, Lasker JM, Lieber CS, et al. Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2. Arch Biochem Biophys 1989; 271: 270–83PubMedCrossRef Raucy JL, Lasker JM, Lieber CS, et al. Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2. Arch Biochem Biophys 1989; 271: 270–83PubMedCrossRef
120.
Zurück zum Zitat Styles JA, Davies A, Lim CK, et al. Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis 1994; 15: 5–9PubMedCrossRef Styles JA, Davies A, Lim CK, et al. Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis 1994; 15: 5–9PubMedCrossRef
121.
Zurück zum Zitat Guengerich FP, Kim DH, Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 1991; 4: 168–79PubMedCrossRef Guengerich FP, Kim DH, Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 1991; 4: 168–79PubMedCrossRef
122.
Zurück zum Zitat Girre C, Lucas D, Hispard E, et al. Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochem Pharmacol 1994; 47(9): 1503–8PubMedCrossRef Girre C, Lucas D, Hispard E, et al. Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochem Pharmacol 1994; 47(9): 1503–8PubMedCrossRef
123.
Zurück zum Zitat de la Maza MP, Hirsch S, Petermann M, et al. Changes in microsomal activity in alcoholism and obesity. Alcohol Clin Exp Res 2000; 24(5): 605–10PubMedCrossRef de la Maza MP, Hirsch S, Petermann M, et al. Changes in microsomal activity in alcoholism and obesity. Alcohol Clin Exp Res 2000; 24(5): 605–10PubMedCrossRef
124.
Zurück zum Zitat Lucas D, Menez C, Girre C, et al. Decrease in cytochrome P4502E1 as assessed by the rate of chlorzoxazone hydroxylation in alcoholics during the withdrawal phase. Alcohol Clin Exp Res 1995; 19(2): 362–6PubMedCrossRef Lucas D, Menez C, Girre C, et al. Decrease in cytochrome P4502E1 as assessed by the rate of chlorzoxazone hydroxylation in alcoholics during the withdrawal phase. Alcohol Clin Exp Res 1995; 19(2): 362–6PubMedCrossRef
125.
Zurück zum Zitat Zaher H, Buters JT, Ward JM, et al. Protection against acetaminophen toxicity in CYP1A2 and CYP2E1 double-null mice. Toxicol Appl Pharmacol 1998; 152(1): 193–9PubMedCrossRef Zaher H, Buters JT, Ward JM, et al. Protection against acetaminophen toxicity in CYP1A2 and CYP2E1 double-null mice. Toxicol Appl Pharmacol 1998; 152(1): 193–9PubMedCrossRef
126.
Zurück zum Zitat Sinclair J, Jeffery E, Wrighton S, et al. Alcohol-mediated increases in acetaminophen hepatotoxicity: role of CYP2E and CYP3A. Biochem Pharmacol 1998; 55(10): 1557–65PubMedCrossRef Sinclair J, Jeffery E, Wrighton S, et al. Alcohol-mediated increases in acetaminophen hepatotoxicity: role of CYP2E and CYP3A. Biochem Pharmacol 1998; 55(10): 1557–65PubMedCrossRef
127.
Zurück zum Zitat McClain CJ, Price S, Barve S, et al. Acetaminophen hepatotoxicity: an update. Curr Gastroenterol Rep 1999; 1(1): 42–9PubMedCrossRef McClain CJ, Price S, Barve S, et al. Acetaminophen hepatotoxicity: an update. Curr Gastroenterol Rep 1999; 1(1): 42–9PubMedCrossRef
129.
Zurück zum Zitat Bessems JG, Vermeulen NP. Paracetamol (acetaminophen)-induced toxicity: molecular and biochemical mechanisms, analogues and protective approaches. Crit Rev Toxicol 2001; 31(1): 55–138PubMedCrossRef Bessems JG, Vermeulen NP. Paracetamol (acetaminophen)-induced toxicity: molecular and biochemical mechanisms, analogues and protective approaches. Crit Rev Toxicol 2001; 31(1): 55–138PubMedCrossRef
130.
Zurück zum Zitat Thummel KE, Slattery JT, Ro H, et al. Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults. Clin Pharmacol Ther 2000; 67(6): 591–9PubMedCrossRef Thummel KE, Slattery JT, Ro H, et al. Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults. Clin Pharmacol Ther 2000; 67(6): 591–9PubMedCrossRef
131.
Zurück zum Zitat Kroemer HK, Gautier JC, Beaune P, et al. Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 1993; 348(3): 332–7PubMedCrossRef Kroemer HK, Gautier JC, Beaune P, et al. Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 1993; 348(3): 332–7PubMedCrossRef
132.
Zurück zum Zitat Busse D, Cosme J, Beaune P, et al. Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 1995; 353(1): 116–21PubMedCrossRef Busse D, Cosme J, Beaune P, et al. Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 1995; 353(1): 116–21PubMedCrossRef
133.
Zurück zum Zitat Ammon E, Klotz U. In-vitro assessment of a possible verapamil/ethanol interaction [abstract]. Naunyn Schmiedebergs Arch Pharmacol 1997; 355: (R123) Ammon E, Klotz U. In-vitro assessment of a possible verapamil/ethanol interaction [abstract]. Naunyn Schmiedebergs Arch Pharmacol 1997; 355: (R123)
134.
Zurück zum Zitat Zacny JP, Yajnik S. Effects of calcium channel inhibitors on ethanol effects and pharmacokinetics in healthy volunteers. Alcohol 1993; 10(6): 505–9PubMedCrossRef Zacny JP, Yajnik S. Effects of calcium channel inhibitors on ethanol effects and pharmacokinetics in healthy volunteers. Alcohol 1993; 10(6): 505–9PubMedCrossRef
135.
Zurück zum Zitat Perez-Reyes M, White WR, Hicks RE. Interaction between ethanol and calcium channel blockers in humans. Alcohol Clin Exp Res 1992; 16(4): 769–75PubMedCrossRef Perez-Reyes M, White WR, Hicks RE. Interaction between ethanol and calcium channel blockers in humans. Alcohol Clin Exp Res 1992; 16(4): 769–75PubMedCrossRef
136.
Zurück zum Zitat Bauer LA, Schumock G, Horn J, et al. Verapamil inhibits ethanol elimination and prolongs the perception of intoxication. Clin Pharmacol Ther 1992; 52(1): 6–10PubMedCrossRef Bauer LA, Schumock G, Horn J, et al. Verapamil inhibits ethanol elimination and prolongs the perception of intoxication. Clin Pharmacol Ther 1992; 52(1): 6–10PubMedCrossRef
137.
Zurück zum Zitat Hecht SS. Inhibition of carcinogenesis by isothiocyanates. Drug Metab Rev 2000; 32(3–4): 395–411PubMedCrossRef Hecht SS. Inhibition of carcinogenesis by isothiocyanates. Drug Metab Rev 2000; 32(3–4): 395–411PubMedCrossRef
138.
Zurück zum Zitat Leclercq I, Desager JP, Horsmans Y. Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress. Clin Pharmacol Ther 1998; 64(2): 144–9PubMedCrossRef Leclercq I, Desager JP, Horsmans Y. Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress. Clin Pharmacol Ther 1998; 64(2): 144–9PubMedCrossRef
139.
Zurück zum Zitat Nakajima M, Yoshida R, Shimada N, et al. Inhibition and inactivation of human cytochrome P450 isoforms by phenethyl isothiocyanate. Drug Metab Dispos 2001; 29(8): 1110–3PubMed Nakajima M, Yoshida R, Shimada N, et al. Inhibition and inactivation of human cytochrome P450 isoforms by phenethyl isothiocyanate. Drug Metab Dispos 2001; 29(8): 1110–3PubMed
140.
Zurück zum Zitat Marchand LL, Wilkinson GR, Wilkens LR. Genetic and dietary predictors of CYP2E1 activity: a phenotyping study in Hawaii Japanese using chlorzoxazone. Cancer Epidemiol Biomarkers Prev 1999; 8(6): 495–500PubMed Marchand LL, Wilkinson GR, Wilkens LR. Genetic and dietary predictors of CYP2E1 activity: a phenotyping study in Hawaii Japanese using chlorzoxazone. Cancer Epidemiol Biomarkers Prev 1999; 8(6): 495–500PubMed
141.
Zurück zum Zitat O’shea D, Davis SN, Kim RB, et al. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther 1994; 56(4): 359–67PubMedCrossRef O’shea D, Davis SN, Kim RB, et al. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther 1994; 56(4): 359–67PubMedCrossRef
142.
Zurück zum Zitat Leclercq I, Horsmans Y, Desager JP, et al. Dietary restriction of energy and sugar results in a reduction in human cytochrome P450 2E1 activity. Br J Nutr 1999; 82(4): 257–62PubMed Leclercq I, Horsmans Y, Desager JP, et al. Dietary restriction of energy and sugar results in a reduction in human cytochrome P450 2E1 activity. Br J Nutr 1999; 82(4): 257–62PubMed
143.
Zurück zum Zitat Tephly TR, Green MD. UDP-glucuronosyltransferases. In: Levy RH, Thummel KE, Trager WF, et al., editors. Metabolic drug interactions. Philadelphia (PA): Lippincott Williams & Wilkins, 2000: 161–74 Tephly TR, Green MD. UDP-glucuronosyltransferases. In: Levy RH, Thummel KE, Trager WF, et al., editors. Metabolic drug interactions. Philadelphia (PA): Lippincott Williams & Wilkins, 2000: 161–74
144.
Zurück zum Zitat Eaton DL, Bammler TK. Glutathione S-transferases. In: Levy RH, Thummel KE, Trager WF, et al., editors. Metabolic drug interactions. Philadelphia (PA): Lippincott Williams & Wilkins, 2000: 175–90 Eaton DL, Bammler TK. Glutathione S-transferases. In: Levy RH, Thummel KE, Trager WF, et al., editors. Metabolic drug interactions. Philadelphia (PA): Lippincott Williams & Wilkins, 2000: 175–90
145.
Zurück zum Zitat Pantuck EJ, Pantuck CB, Anderson KE, et al. Effect of brussels sprouts and cabbage on drug conjugation. Clin Pharmacol Ther 1984; 35(2): 161–9PubMedCrossRef Pantuck EJ, Pantuck CB, Anderson KE, et al. Effect of brussels sprouts and cabbage on drug conjugation. Clin Pharmacol Ther 1984; 35(2): 161–9PubMedCrossRef
146.
Zurück zum Zitat Court MH, Duan SX, von Moltke LL, et al. Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther 2001; 299(3): 998–1006PubMed Court MH, Duan SX, von Moltke LL, et al. Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther 2001; 299(3): 998–1006PubMed
147.
Zurück zum Zitat Patel M, Tang BK, Kalow W. (S)-Oxazepam glucuronidation is inhibited by ketoprofen and other substrates of UGT2B7. Pharmacogenetics 1995; 5(1): 43–9PubMedCrossRef Patel M, Tang BK, Kalow W. (S)-Oxazepam glucuronidation is inhibited by ketoprofen and other substrates of UGT2B7. Pharmacogenetics 1995; 5(1): 43–9PubMedCrossRef
148.
Zurück zum Zitat Coffman BL, King CD, Rios GR, et al. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos 1998; 26(1): 73–7PubMed Coffman BL, King CD, Rios GR, et al. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos 1998; 26(1): 73–7PubMed
149.
Zurück zum Zitat Hecht SS, Carmella SG, Murphy SE. Effects of watercress consumption on urinary metabolites of nicotine in smokers. Cancer Epidemiol Biomarkers Prev 1999; 8(10): 907–13PubMed Hecht SS, Carmella SG, Murphy SE. Effects of watercress consumption on urinary metabolites of nicotine in smokers. Cancer Epidemiol Biomarkers Prev 1999; 8(10): 907–13PubMed
150.
Zurück zum Zitat Bogaards JJ, Verhagen H, Willems MI, et al. Consumption of Brussels sprouts results in elevated alpha-class glutathione S-transferase levels in human blood plasma. Carcinogenesis 1994; 15(5): 1073–5PubMedCrossRef Bogaards JJ, Verhagen H, Willems MI, et al. Consumption of Brussels sprouts results in elevated alpha-class glutathione S-transferase levels in human blood plasma. Carcinogenesis 1994; 15(5): 1073–5PubMedCrossRef
151.
Zurück zum Zitat Nijhoff WA, Mulder TP, Verhagen H, et al. Effects of consumption of brussels sprouts on plasma and urinary glutathione S-transferase class-alpha and -pi in humans. Carcinogenesis 1995; 16(4): 955–7PubMedCrossRef Nijhoff WA, Mulder TP, Verhagen H, et al. Effects of consumption of brussels sprouts on plasma and urinary glutathione S-transferase class-alpha and -pi in humans. Carcinogenesis 1995; 16(4): 955–7PubMedCrossRef
152.
Zurück zum Zitat Nijhoff WA, Grubben MJ, Nagengast FM, et al. Effects of consumption of Brussels sprouts on intestinal and lymphocytic glutathione S-transferases in humans. Carcinogenesis 1995; 16(9): 2125–8PubMedCrossRef Nijhoff WA, Grubben MJ, Nagengast FM, et al. Effects of consumption of Brussels sprouts on intestinal and lymphocytic glutathione S-transferases in humans. Carcinogenesis 1995; 16(9): 2125–8PubMedCrossRef
153.
Zurück zum Zitat Lampe JW, Chen C, Li S, et al. Modulation of human glutathione S-transferases by botanically defined vegetable diets. Cancer Epidemiol Biomarkers Prev 2000; 9(8): 787–93PubMed Lampe JW, Chen C, Li S, et al. Modulation of human glutathione S-transferases by botanically defined vegetable diets. Cancer Epidemiol Biomarkers Prev 2000; 9(8): 787–93PubMed
154.
Zurück zum Zitat Benet LZ, Cummins CL. The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Deliv Rev 2001; 50(1 Suppl.): 3S–11SCrossRef Benet LZ, Cummins CL. The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Deliv Rev 2001; 50(1 Suppl.): 3S–11SCrossRef
155.
Zurück zum Zitat Spahn-Langguth H, Langguth P. Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur J Pharm Sci 2001; 12(4): 361–7PubMedCrossRef Spahn-Langguth H, Langguth P. Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur J Pharm Sci 2001; 12(4): 361–7PubMedCrossRef
156.
Zurück zum Zitat Bistrup C, Nielsen FT, Jeppesen UE, et al. Effect of grapefruit juice on Sandimmun Neoral absorption among stable renal allograft recipients. Nephrol Dial Transplant 2001; 16(2): 373–7PubMedCrossRef Bistrup C, Nielsen FT, Jeppesen UE, et al. Effect of grapefruit juice on Sandimmun Neoral absorption among stable renal allograft recipients. Nephrol Dial Transplant 2001; 16(2): 373–7PubMedCrossRef
157.
Zurück zum Zitat Becquemont L, Verstuyft C, Kerb R, et al. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther 2001; 70(4): 311–6PubMed Becquemont L, Verstuyft C, Kerb R, et al. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther 2001; 70(4): 311–6PubMed
158.
Zurück zum Zitat Westphal K, Weinbrenner A, Giessmann T, et al. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther 2000; 68(1): 6–12PubMedCrossRef Westphal K, Weinbrenner A, Giessmann T, et al. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther 2000; 68(1): 6–12PubMedCrossRef
159.
Zurück zum Zitat Boyd RA, Stern RH, Stewart BH, et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol 2000; 40(1): 91–8PubMedCrossRef Boyd RA, Stern RH, Stewart BH, et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol 2000; 40(1): 91–8PubMedCrossRef
160.
Zurück zum Zitat Dresser GK, Bailey DG, Leake BF, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002; 71(1): 11–20PubMedCrossRef Dresser GK, Bailey DG, Leake BF, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002; 71(1): 11–20PubMedCrossRef
161.
Zurück zum Zitat Johne A, Brockmoller J, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John’s wort (Hypericum perforatum). Clin Pharmacol Ther 1999; 66(4): 338–45PubMedCrossRef Johne A, Brockmoller J, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John’s wort (Hypericum perforatum). Clin Pharmacol Ther 1999; 66(4): 338–45PubMedCrossRef
162.
Zurück zum Zitat Kovarik JM, Rigaudy L, Guerret M, et al. Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin. Clin Pharmacol Ther 1999; 66(4): 391–400PubMedCrossRef Kovarik JM, Rigaudy L, Guerret M, et al. Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin. Clin Pharmacol Ther 1999; 66(4): 391–400PubMedCrossRef
163.
Zurück zum Zitat GreinerB, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104(2): 147–53CrossRef GreinerB, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104(2): 147–53CrossRef
164.
Zurück zum Zitat Durr D, Stieger B, Kullak-Ublick GA, et al. St John’s Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000; 68(6): 598–604PubMedCrossRef Durr D, Stieger B, Kullak-Ublick GA, et al. St John’s Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000; 68(6): 598–604PubMedCrossRef
165.
Zurück zum Zitat Krishnaswamy K, Kalamegham R, Naidu NA. Dietary influences on the kinetics of antipyrine and aminopyrine in human subjects. Br J Clin Pharmacol 1984; 17(2): 139–46PubMedPubMedCentralCrossRef Krishnaswamy K, Kalamegham R, Naidu NA. Dietary influences on the kinetics of antipyrine and aminopyrine in human subjects. Br J Clin Pharmacol 1984; 17(2): 139–46PubMedPubMedCentralCrossRef
166.
Zurück zum Zitat Kappas A, Anderson KE, Conney AH, et al. Influence of dietary protein and carbohydrate on antipyrine and theophyl-line metabolism in man. Clin Pharmacol Ther 1976; 20(6): 643–53PubMedCrossRef Kappas A, Anderson KE, Conney AH, et al. Influence of dietary protein and carbohydrate on antipyrine and theophyl-line metabolism in man. Clin Pharmacol Ther 1976; 20(6): 643–53PubMedCrossRef
167.
Zurück zum Zitat Fagan TC, Walle T, Oexmann MJ, et al. Increased clearance of propranolol and theophylline by high-protein compared with high-carbohydrate diet. Clin Pharmacol Ther 1987; 41(4): 402–6PubMedCrossRef Fagan TC, Walle T, Oexmann MJ, et al. Increased clearance of propranolol and theophylline by high-protein compared with high-carbohydrate diet. Clin Pharmacol Ther 1987; 41(4): 402–6PubMedCrossRef
168.
Zurück zum Zitat Jorquera F, Almar M, Martinez C, et al. Antipyrine clearance in surgical patients maintained on hypocaloric peripheral paren-teral nutrition. JPEN J Parenter Enterai Nutr 1994; 18(6): 544–8CrossRef Jorquera F, Almar M, Martinez C, et al. Antipyrine clearance in surgical patients maintained on hypocaloric peripheral paren-teral nutrition. JPEN J Parenter Enterai Nutr 1994; 18(6): 544–8CrossRef
169.
Zurück zum Zitat Burgess P, Hall RI, Bateman DN, et al. The effect of total parenteral nutrition on hepatic drug oxidation. JPEN J Parenter Enterai Nutr 1987; 11(6): 540–3CrossRef Burgess P, Hall RI, Bateman DN, et al. The effect of total parenteral nutrition on hepatic drug oxidation. JPEN J Parenter Enterai Nutr 1987; 11(6): 540–3CrossRef
170.
Zurück zum Zitat Hoensch HP, Steinhardt HJ, Weiss G, et al. Effects of semisynthetic diets on xenobiotic metabolizing enzyme activity and morphology of small intestinal mucosa in humans. Gastroenterology 1984; 86(6): 1519–30PubMed Hoensch HP, Steinhardt HJ, Weiss G, et al. Effects of semisynthetic diets on xenobiotic metabolizing enzyme activity and morphology of small intestinal mucosa in humans. Gastroenterology 1984; 86(6): 1519–30PubMed
171.
Zurück zum Zitat Maliakal PP, Wanwimolruk S. Effect of herbal teas on hepatic drug metabolizing enzymes in rats. J Pharm Pharmacol 2001; 53(10): 1323–9PubMedCrossRef Maliakal PP, Wanwimolruk S. Effect of herbal teas on hepatic drug metabolizing enzymes in rats. J Pharm Pharmacol 2001; 53(10): 1323–9PubMedCrossRef
172.
Zurück zum Zitat Kusamran WR, Ratanavila A, Tepsuwan A. Effects of neem flowers, Thai and Chinese bitter gourd fruits and sweet basil leaves on hepatic monooxygenases and glutathione S-transferase activities, and in vitro metabolic activation of chemical carcinogens in rats. Food Chem Toxicol 1998; 36(6): 475–84PubMedCrossRef Kusamran WR, Ratanavila A, Tepsuwan A. Effects of neem flowers, Thai and Chinese bitter gourd fruits and sweet basil leaves on hepatic monooxygenases and glutathione S-transferase activities, and in vitro metabolic activation of chemical carcinogens in rats. Food Chem Toxicol 1998; 36(6): 475–84PubMedCrossRef
173.
Zurück zum Zitat Sohn OS, Surace A, Fiala ES, et al. Effects of green and black tea on hepatic xenobiotic metabolizing systems in the male F344 rat. Xenobiotica 1994; 24(2): 119–27PubMedCrossRef Sohn OS, Surace A, Fiala ES, et al. Effects of green and black tea on hepatic xenobiotic metabolizing systems in the male F344 rat. Xenobiotica 1994; 24(2): 119–27PubMedCrossRef
174.
Zurück zum Zitat Obermeier MT, White RE, Yang CS. Effects of bioflavonoids on hepatic P450 activities. Xenobiotica 1995; 25(6): 575–84PubMedCrossRef Obermeier MT, White RE, Yang CS. Effects of bioflavonoids on hepatic P450 activities. Xenobiotica 1995; 25(6): 575–84PubMedCrossRef
175.
Zurück zum Zitat Umegaki K, Ikegami S. Feeding fish oil to rats accelerates the metabolism of hexachlorobenzene. J Nutr Sci Vitaminol (Tokyo) 1998; 44(2): 301–11CrossRef Umegaki K, Ikegami S. Feeding fish oil to rats accelerates the metabolism of hexachlorobenzene. J Nutr Sci Vitaminol (Tokyo) 1998; 44(2): 301–11CrossRef
Metadaten
Titel
Dietary Effects on Drug Metabolism and Transport
verfasst von
Dr Robert Z. Harris
Graham R. Jang
Shirley Tsunoda
Publikationsdatum
01.11.2003
Verlag
Springer International Publishing
Erschienen in
Clinical Pharmacokinetics / Ausgabe 13/2003
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200342130-00001

Weitere Artikel der Ausgabe 13/2003

Clinical Pharmacokinetics 13/2003 Zur Ausgabe